Tirzepatide vs Semaglutide for Obesity: Head-to-Head Network Meta-Analysis | Research

The takeaway

Network meta-analysis suggests tirzepatide outperforms semaglutide for weight loss and glycemic improvement in people with obesity.

Tirzepatide > semaglutide
Dual GIP/GLP-1 agonist outperformed GLP-1 alone for weight loss and glycemic control in NMA

What the researchers found

Network meta-analysis of RCTs indicates tirzepatide (dual GIP/GLP-1 agonist) provides greater body weight reduction and glycemic improvement compared to semaglutide (GLP-1 agonist alone) in obesity.

Why it matters

This directly addresses the most common clinical question in obesity pharmacotherapy: which of the two leading drugs should I prescribe?

How the study worked

Network meta-analysis using a frequentist approach, comparing RCTs of tirzepatide or semaglutide versus placebo or active comparators for obesity treatment.

What this study cannot tell us

Network meta-analysis relies on indirect comparisons across different trials. Patient populations, dosing, and follow-up may not be directly comparable. Few head-to-head RCTs exist.

How to read the evidence

Network meta-analysis of RCTs — strong evidence synthesis, though mostly indirect comparisons.

When this study was published

Published in 2026; includes the latest obesity trial data for both drugs.

The bigger picture

The dual-agonist approach (targeting GIP + GLP-1) appears to provide additional benefits beyond single-receptor GLP-1 agonism, validating the multi-target strategy in obesity pharmacotherapy.

Questions still open

Does tirzepatide's advantage extend to cardiovascular and other long-term outcomes?
Are the side effect profiles different enough to influence prescribing decisions?

Common questions

Is tirzepatide better than semaglutide for weight loss?

This meta-analysis suggests tirzepatide produces somewhat greater weight loss than semaglutide, likely because it targets two hormone receptors (GIP and GLP-1) instead of one. Individual results may vary.

Should I switch from semaglutide to tirzepatide?

That depends on your individual response, insurance coverage, and tolerability. While this analysis favors tirzepatide overall, many patients do very well on semaglutide. Discuss switching with your doctor.

Read the original research

Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide.

Journal of diabetes, 18(2), e70192

View on PubMed ↗Publisher’s paper ↗

Citation

Bernardi, Julia C; Cavalcante, Deivyd V S; Huntermann, Ramon; Molinari, Maria E; Zanon, Luana Z; Khater, Jacinthe; Gomez, Victor A; Fischer-Bacca, Caroline O. (2026). Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide.. Journal of diabetes, 18(2), e70192. https://doi.org/10.1111/1753-0407.70192